Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment.

Weitzenböck, Hans Peter; Gschwendtner, Anna; Wiesner, Christoph; Depke, Maren; Schmidt, Frank; Trautinger, Franz; Hengstschläger, Markus; Hundsberger, Harald; Mikula, Mario

Weitzenböck, Hans Peter; Gschwendtner, Anna; Wiesner, Christoph; Depke, Maren; Schmidt, Frank; Trautinger, Franz; Hengstschläger, Markus; Hundsberger, Harald; Mikula, Mario.

Afiliación

Weitzenböck HP; Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences, Krems, Austria.
Gschwendtner A; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
Wiesner C; Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences, Krems, Austria.
Depke M; Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.
Schmidt F; Proteomics Core, Weill Cornell Medicine-Qatar, Qatar Foundation-Education City, Doha, Qatar.
Trautinger F; Department of Dermatology and Venereology, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria.
Hengstschläger M; Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria.
Hundsberger H; Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
Mikula M; Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences, Krems, Austria.

Cancer Med ; 11(4): 956-967, 2022 02.

Article en En | MEDLINE | ID: mdl-34951143

Asunto(s)

Melanoma; Proteoma; Apoptosis; Línea Celular Tumoral; Humanos; Receptores de Hialuranos/genética; Receptores de Hialuranos/metabolismo; Melanoma/tratamiento farmacológico; Melanoma/genética; Melanoma/metabolismo; Factor 2 Relacionado con NF-E2/genética; Factor 2 Relacionado con NF-E2/metabolismo; Proteoma/metabolismo; Proteínas Proto-Oncogénicas B-raf/genética; Regulación hacia Arriba; Vemurafenib/farmacología

Palabras clave

anti-oxidant response; combination therapy; malignant melanoma; redox homeostasis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteoma / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2022 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google